Scrip Dividend - total issued shares
Updated : 14:30
ConvaTec Group Plc
Scrip Dividend - total issued shares
Reading, United Kingdom (29 April 2019)
On 12 February 2019, the Board of Directors of ConvaTec Group Plc ("ConvaTec" or "the Company") proposed a final dividend in respect of 2018, subject to shareholder approval at the Annual General Meeting on 9 May 2019 of 3.983 cents per share (the "final dividend"). This final dividend is to be paid on 16 May 2019 to shareholders on the share register as at 5 April 2019. The dividend is payable in cash in Sterling to holders of ordinary shares. On 14 February 2019, the Company announced that a Scrip Dividend Scheme will be made available for this final dividend allowing shareholders to elect to receive their dividend in the form of new ordinary shares. The calculation price for the Scrip Dividend Scheme was announced on 11 April 2019.
It is confirmed that 11,198,285 ordinary shares of 10 pence each will be allotted and issued on 16 May 2019 by the Company to those shareholders who elected to receive the scrip dividend alternative. The shares will rank pari passu with the existing issued ordinary shares of the Company. Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List and to the London Stock Exchange for the shares to be admitted to trading.
Dealings in the shares issued under the scrip dividend scheme is expected to commence on 16 May 2019.
TIMETABLE
Key dates in respect of the scrip dividend scheme for the final dividend are:
Ex-dividend Date | 4 April 2019 |
Record Date | 5 April 2019 |
Scrip calculation price determined | 4-10 April 2019 (inclusive) |
Scrip calculation price available and announced | 11 April 2019 |
Mandate delivery deadline for Shares held in uncertificated form | 3.00 p.m. on 23 April 2019 |
Mandate delivery deadline for Shares held in certificated form | 5.00 p.m. on 23 April 2019 |
Announcement of the total amount of new shares to be issued | 29 April 2019 |
Dividend payment date | 16 May 2019 |
Dispatch of statement in accordance with section 7 of Scheme Rules and share certificates, CREST accounts credited/updated, and first day of dealings in New Shares | 16 May 2019 |
Enquiries
Media
Bobby Leach, VP Group Corporate Affairs, ConvaTec +44 (0)7770 842 226
Alastair Elwen, Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, ConvaTec +44 (0)7500 141 435
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
investorrelations@convatec.com
LEI: 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
# # #
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.